<span item_type="fundamental" item_id="25b269a91984192cebb6e43db1f05ac3" counter_id="ST/US/DRMAW" env="prod"></span><span item_type="announcement" item_id="549093516593987841" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -1.66.</p><p></p><h3>Segment Revenue</h3><ul><li>Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025. The funds are expected to fund operations into the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development expenses were $0.6 million for the quarter ended June 30, 2025, compared to $2.0 million for the quarter ended June 30, 2024. The $1.4 million decrease was primarily due to decreased clinical expenses from the XYNGARI™ STAR-1 acne study.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li><li>General and administrative expenses were $1.2 million for the quarter ended June 30, 2025, compared to $0.9 million for the same period in 2024. The $0.3 million increase was due to increased public company compliance costs and personnel costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li><li>Net loss for the quarter ended June 30, 2025, was $1.7 million, compared to $2.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of June 30, 2025, the company had $6.5 million in cash and cash equivalents, compared to $3.2 million as of December 31, 2024. The $3.3 million increase resulted from approximately $7.9 million of net financing proceeds offset by $4.6 million of cash used in operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company highlighted positive topline data from its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne, achieving statistically significant results for its three co-primary endpoints at weeks 4 and 12.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company expects its current cash resources to be sufficient to fund operations into the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li><li>The company is evaluating next steps with respect to the XYNGARI™ Phase 3 STAR-2 clinical trial, which would be followed by a 9-month extension study.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm"></span></li></ul>

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2025 Q2 EPS: USD -1.66